p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Clinical trial NCT02846935 · COMPLETED
Trial details
- NCT number
- NCT02846935
- Sponsor
- Yogen Saunthararajah
- Status
- COMPLETED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-25
- Primary completion
- 2018-01-22
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.